A nurse is assisting to provide an in-service to a group of nurses on medications used to treat the progression of dementia. Which of the following medications should the nurse include in the teaching?

A. Aducanumab is a disease-modifying monoclonal antibody therapy approved for the treatment of Alzheimer’s disease. It works by targeting amyloid-beta plaques in the brain, which are believed to contribute to the neurodegenerative process that underlies dementia. The primary goal of aducanumab is to slow the progression of cognitive decline, not simply to treat symptoms such as memory loss or confusion. This makes it different from traditional dementia medications that are mainly symptomatic treatments. Including aducanumab in an in-service for nurses emphasizes current therapeutic advances in modifying the disease course and provides an opportunity to discuss administration, monitoring, and patient education. B. Levodopa is a dopaminergic medication used to manage the motor symptoms of Parkinson’s disease, such as tremor, rigidity, and bradykinesia. It does not impact the pathophysiology of dementia, and therefore is not relevant for slowing cognitive decline in Alzheimer’s disease. C. Tetrabenazine is used for hyperkinetic movement disorders, like chorea in Huntington’s disease. It has no role in treating dementia or modifying Alzheimer’s disease progression. D. Warfarin is an anticoagulant used to prevent thromboembolic events. While it may be prescribed to a patient who has coexisting cardiovascular disease, it does not affect the progression of cognitive decline and is unrelated to dementia management.